US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myeloma

  The US Food and Drug Administration (FDA – the medicines regulator in the US) has granted approval to a “supplemental biologics license application” for teclistamab-cqvy (Tecvayli®). This means the existing FDA teclistamab license has been extended to include administration at a reduced dosing frequency of 1.5 mg/kg every two weeks, instead of once weekly (as is currently the case) for patients with relapsed/refractory myeloma who have maintained a sustained complete response (CR – a…

Sign up for the MPE webinar “Basics of medicines pricing in Europe”

Myeloma Patients Europe (MPE) will hold the webinar “Basics of medicines pricing in Europe” on Thursday 7th March 2024 from 15:00 – 16:30 CET. Through this webinar you will understand the basics of drug pricing (with a focus on high-cost branded medicines) and the processes and policies that influence it. The webinar will be given by Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies and Head of Pharmacoeconomics Department,…

ASH 2023 | Myeloma and AL amyloidosis updates

Myeloma Patients Europe (MPE) attended the 65th American Society of Hematology (ASH) Annual Meeting, the largest haematology congress, held from 9 to 12 December in San Diego (United States). MPE has interviewed haematology experts to summarise the latest myeloma and AL amyloidosis updates.     Prof. Dr. Michel Delforge, Department of Haematology, University Hospital Leuven, Belgium, explains the latest findings on the KarMMa-3 trial and the impact abecma has on Quality of Life (QoL) presented at…

EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisation

The European Medicines Agency (the EU medicines regulator) Committee for Medicinal Products for Human Use (CHMP) has today confirmed their earlier recommendation to not renew marketing authorisation for belamaf mafadotin (Blenrep®). The confirmation follows a review of the CHMP decision, requested by the manufacturer GSK. MPE Co-Chief Executive Officer, Kate Morgan, commented: “The final recommendation from the EMA CHMP is a disappointing one. Whilst we understand the limitations from the DREAMM-3 clinical trial data, we…

Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlights

Myeloma Patients Europe (MPE) will host a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the 65th American Society of Hematology (ASH) Annual Meeting which will be held 9-12 December, 2023 in San Diego, California, United States.   The webinar will take place on Wednesday, 17 January from 17:00 to 18:00 CET and will be given by Dr. Faith Davies, Director of Clinical Myeloma Programme at NYU Langone Health Perlmutter…

2023: Year in Review

On behalf of the Myeloma Patients Europe (MPE) Board of Directors and staff, we extend a heartfelt thank you to our members, sponsors and stakeholders for your dedication and inspiration.   This year, MPE achieved significant milestones made possible by our collective efforts, and we are thrilled to present our Year in Review 2023. We hope you’ll take a moment to read this report, which highlights our key accomplishments focused on empowering, educating and supporting the patient…

MPE launches a report focused on the impact of AL amyloidosis in quality of life

AL amyloidosis is a rare condition and limited research on patient perspectives and needs exists. With the aim to better understand patients’ experiences regarding AL amyloidosis diagnosis and treatment, and how these impact on quality of life, MPE conducted qualitative research and published the report “Health-related quality of life, diagnosis and treatment experiences of AL amyloidosis patients.” According to this report, “receiving a diagnosis of AL amyloidosis can make people feel as if they have…

ESMO 2023 | Patient Advocacy Track highlights challenges in access, caregiver support and digitalisation

35.000 people attended the European Society for Medical Oncology (ESMO) Annual Congress, held from 20 to 24 October in Madrid, Spain, where the latest data in oncology research and development was presented. Along with several updates, mostly in solid tumours, different advocacy topics were discussed as part of the Patient Advocacy Track. Myeloma Patients Europe (MPE) was represented by Kate Morgan, MPE Co-Chief Executive Officer, and Lise-lott Eriksson, MPE president who participated in one of…

MPE to present at European Society for Medical Oncology (ESMO) Annual Congress 2023

Myeloma Patients Europe (MPE) will present as part of the Patient Advocacy Track at the European Society for Medical Oncology (ESMO) Annual Congress. The Congress will be held from 20 to 24 October in Madrid, Spain where the latest data in oncology research and development will be presented. Kate Morgan, MPE Co-Chief Executive Officer, and Lise-lott Eriksson, MPE Board President, will each give a talk during the patient advocacy session, “How to improve access to…